| Not Yet Recruiting | Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initi NCT06706219 | Hunan Province Tumor Hospital | Phase 2 |
| Recruiting | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 NCT06449313 | Georgetown University | Phase 2 |
| Recruiting | Pulmonary Rehabilitation in Advanced Lung Cancer Survivors NCT07104630 | Case Comprehensive Cancer Center | Phase 2 |
| Recruiting | HEARTS Trial for Thoracic Cancers NCT07132918 | University of Wisconsin, Madison | Phase 2 |
| Not Yet Recruiting | The IVO-LUNG Study NCT07204548 | Sun Yat-sen University | Phase 2 |
| Not Yet Recruiting | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage NCT06998719 | Bi Nan | Phase 2 |
| Not Yet Recruiting | The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable NCT06962189 | Zhejiang University | Phase 2 |
| Not Yet Recruiting | Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC NCT06908733 | Liaoning Cancer Hospital & Institute | Phase 2 |
| Recruiting | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab NCT06908070 | Idris Bahce | Phase 4 |
| Recruiting | Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients NCT06634199 | Fundación GECP | — |
| Recruiting | Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint NCT06463665 | Genelux Corporation | Phase 2 |
| Unknown | Combining ICI With SBRT or HypoFrx-RT for ES NSCLC NCT05451173 | Alexander Chi | Phase 1 / Phase 2 |
| Unknown | Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy NCT06031597 | Zhejiang Cancer Hospital | Phase 3 |
| Not Yet Recruiting | Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC NCT05548504 | Odense University Hospital | Phase 2 |
| Recruiting | Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly And/or Frail Stage III Non-small-cell Lu NCT05557552 | Ruijin Hospital | N/A |
| Recruiting | Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer NCT04728724 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Active Not Recruiting | Response and Toxicity Prediction by Microbiome Analysis After (Concurrent) Chemoradiotherapy NCT04711330 | Leiden University Medical Center | — |
| Withdrawn | Quantifying Systemic Immunosuppression to Personalize Cancer Therapy NCT04941365 | Institut du Cancer de Montpellier - Val d'Aurelle | N/A |
| Unknown | A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant No NCT05338619 | Sung Yong Lee | Phase 2 |
| Active Not Recruiting | Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment NCT05382052 | Fundación GECP | — |
| Unknown | A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer NCT05414630 | Anhui Provincial Cancer Hospital | Phase 2 |
| Recruiting | Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radioth NCT05398094 | Fundación GECP | Phase 2 |
| Active Not Recruiting | Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-smal NCT04685070 | Shanghai Pulmonary Hospital, Shanghai, China | Phase 2 |
| Terminated | Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC NCT04765709 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Terminated | Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During T NCT04878952 | NRG Oncology | N/A |
| Recruiting | Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) NCT04585477 | Stanford University | Phase 2 |
| Completed | Accelerated Radio-Immunotherapy for Lung Cancer NCT04577638 | Center Eugene Marquis | Phase 2 |
| Unknown | Biomarkers of Stage III Locally Advanced Unresectable Non-small-cell Lung Cancer NCT04749407 | First People's Hospital of Hangzhou | — |
| Active Not Recruiting | Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy NCT04716946 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Dose-painting Radiation for LA-NSCLC NCT05031533 | Sichuan Cancer Hospital and Research Institute | N/A |
| Unknown | Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC NCT04586465 | Fifth Affiliated Hospital, Sun Yat-Sen University | Phase 2 |
| Not Yet Recruiting | Efficacy and Safety of CRT, Durvalumab and Surgery for SST NCT04465968 | National Cancer Center Hospital East | Phase 3 |
| Unknown | A Real-world Study of Durvalumab for Lung Cancer in China NCT04672759 | Peking Union Medical College Hospital | — |
| Terminated | Tumor Mutational Burden in Lung Cancer Patients NCT04289259 | Assistance Publique - Hôpitaux de Paris | — |
| Active Not Recruiting | Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study NCT04392505 | Oslo University Hospital | Phase 2 |
| Completed | The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definit NCT06015815 | Ankara University | — |
| Completed | Her2-positive Lung Cancer Treated With Dedicated Drug NCT03845270 | Intergroupe Francophone de Cancerologie Thoracique | Phase 2 |
| Completed | Anlotinib After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer（ALTER-L029） NCT03743129 | Anhui Shi, MD | Phase 2 |
| Completed | A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer NCT03728556 | CStone Pharmaceuticals | Phase 3 |
| Active Not Recruiting | A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unrese NCT03521154 | AstraZeneca | Phase 3 |
| Completed | High Intensity Functional Image Guided Vmat Lung Evasion NCT03569072 | Peter MacCallum Cancer Centre, Australia | N/A |
| Completed | Oncoxin® and Quality of Life in Cancer Patients NCT03550482 | Catalysis SL | Phase 4 |
| Completed | Prognostic Evaluation of Tumor Volume and Its Changes in Radical Radiotherapy of Advanced NSCLC NCT03055715 | Martin-Luther-Universität Halle-Wittenberg | — |
| Unknown | ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC NCT02946216 | First People's Hospital of Hangzhou | — |
| Completed | EGFR Mutations on ctDNA in Patients With Advanced NSCLC NCT02623257 | First People's Hospital of Hangzhou | — |
| Recruiting | Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Pa NCT02622581 | AIO-Studien-gGmbH | — |
| Completed | NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B NCT02434081 | ETOP IBCSG Partners Foundation | Phase 2 |
| Terminated | A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based NCT02412371 | AbbVie | Phase 1 / Phase 2 |
| Completed | T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure NCT02418234 | First People's Hospital of Hangzhou | — |
| Unknown | An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income Countries NCT02247713 | The Netherlands Cancer Institute | — |
| Completed | Pilot Study of a Novel Type of CT Scan to Assess Treatment Response During Chemoradiotherapy for Stage III Non NCT02053285 | Rush University Medical Center | — |
| Unknown | Erlotinib in Post Radical Operation NSCLC Patients With EGFR Mutation NCT01683175 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Completed | Evaluation of Cancer Care Coordination in the National Cancer Institutes Community Cancer Center Programs NCT01346280 | National Cancer Institute (NCI) | — |
| Withdrawn | Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) NCT00903942 | University of Rochester | Phase 2 |